1. Introduction {#s0005}
===============

Oral submucous fibrosis (OSF) is a persistent condition that affects the oral cavity and sometimes affects the pharynx. Infrequently the disease starts as a vesicle formation, but it is always affiliated with juxtaepithelial inflammation and fibrotic changes in the connective tissue leading to rigid oral mucosa causing inability to eat ([@b0095]). OSF occurs as a result of habitually chewing the areca nut in various forms. Recently most of the subjects with OSF are in the young age group ([@b0105]). Around 600 million people chew areca nut worldwide. However it is very commonly used by south Asian populations. Approximately 2.5 million people worldwide suffer from OSF ([@b0060]).

The initial stage of the disease is usually characterized by atrophic and blanching oral mucosal epithelium. Vesicles and erosive lesions may also develop in some patients. As the disease advances, fibrotic band formation leads to characteristic mouth opening restriction ([@b0040]). It is observed that the band formation initiates posteriorly and progresses anteriorly, which leads to a progressive decline in the mouth opening ability of a person with disease progression. After the disease reaches the fibrosis stage, there will not be complete resolution even if the subject stops the habit completely ([@b0100]). The disease is considered a premalignant condition with a malignant potential of about 7.6% having a prevalence of about 0.2--0.5% ([@b0020], [@b0015]).

Assessment of mouth opening ability is used as one of the procedures to appraise the disease severity. Many of the OSF staging systems do not consider the limit of normal mouth opening in a person when assessing reduction in mouth opening. The normal level of mouth opening fluctuates from population to population and from person to person ([@b0030], [@b0010]). Hence a mere measurement of reduced mouth opening without assessing normal mouth opening may not be appropriate for staging OSF. The normal maximum mouth opening capacity of an individual has been considered in this study to assess the reduction in mouth opening.

2. Materials and methods {#s0010}
========================

2.1. Ethical clearance {#s0015}
----------------------

The University ethical committee approved the study, and the ethical clearance was obtained. All of the participants were informed that participation was voluntary; they had all been given the choice to discontinue at any step of the study. The complete procedure was described to all of the subjects in detail, and informed consent was obtained from each of them.

2.2. Sample selection {#s0020}
---------------------

The present study was performed in the Oral Medicine and Radiology department. A total of 50 patients between the ages of 20 and 50 years old who had been clinically diagnosed with OSF were included in this study.

2.3. Eligibility criteria {#s0025}
-------------------------

Those patients with a history of deleterious areca nut chewing reported to the department with such clinical features as a burning sensation, blanching, presence of vertical fibrous bands involving the oral cavity, and reduced mouth opening. Both male and female gender groups in the age range of 20--50 years were selected. Patients with complex medical conditions, traumatic injuries to maxillofacial structures, and who were not willing to be biopsied were excluded from the study.

2.4. Personal data recording {#s0030}
----------------------------

Patient data including name, age, gender, occupation, and race were recorded. A detailed report regarding the deleterious habit of chewing areca nut in any form and the frequency and duration of its usage were obtained from the patients. It was then followed by proper clinical examination.

2.5. Clinical evaluation {#s0035}
------------------------

All of the subjects were assessed for the presence of blanching, rigidity of oral mucosa, palpable vertical bands, and interincisal mouth opening. The measurement was done by using a calibrated Vernier caliper and recorded in millimetres by measuring the maximum mouth opening (MMO) from the 'mesioincisal edge of the upper left central incisor tooth to the mesioincisal edge of the lower left central incisor tooth' ([Fig. 1](#f0005){ref-type="fig"}). Clinical staging was done as 'stage I, which has only faucial bands, stage II having faucial and buccal bands, and stage III consisting of faucial, buccal, and labial bands,' according to [@b0040].Fig. 1Showing maximum mouth opening (MMO) measurement using Vernier caliper.

2.6. Assessment of normal mouth opening {#s0040}
---------------------------------------

The patients' normal mouth opening was established by measuring the three finger (index, middle, and ring fingers) width. The measurements were done at distal interphalangeal folds using a calibrated Vernier caliper and recorded in millimetres ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Showing measurement of three finger index (TFI).

2.7. Assessment of percentage of reduction in mouth opening {#s0045}
-----------------------------------------------------------

The percentage of reduction in mouth opening (PRMO) was calculated by subtracting the maximum mouth opening (MMO) from the three finger width (TFI) in millimetres.$${\text{PRMO\ =}\mspace{6mu}}\frac{\text{TFI} - \text{MMO} \times \text{100}}{\text{TFI}}$$

2.8. Biopsy procedure {#s0050}
---------------------

All of the patients were subjected to incisional biopsy, and the histologic gradings were obtained according to the criteria proposed by [@b0095].

2.9. Statistical analysis {#s0055}
-------------------------

All 50 samples were clinically staged from stage I to stage III, and the mean of PRMO was calculated in each stage and correlated using Fisher's exact test. All 50 samples were grouped into four groups histologically, according to the Pindborg and Sirsat staging system, and the mean value of PRMO was calculated in each group ([@b0095]). The mean values of the four groups were compared from stage I to stage IV using Fisher's exact test. Thu a new staging pattern was proposed for OSF from the obtained data.

3. Results {#s0060}
==========

3.1. Age- and gender-wise assessment in study group ([Table 1](#t0005){ref-type="table"}) {#s0065}
-----------------------------------------------------------------------------------------

The age range in the study group was from 20 to 50 years old with a mean age of 28.94 years. The maximum number of patients (70%) were in the 20- to 30-year-old age group. There were 11 subjects (22%) in the 30- to 40-year-old range and 4 subjects (8%) in the above-40-years-old range. Among the total of 50 patients; 47 were males and 3 were females.Table 1Age and gender wise assessment in study group.Number of participantsPercentageAge group20--30 years3570%30--40 years1122%\>40 years48%  Total50100%  GenderMales4794%Females36%  Total50100%

3.2. Assessment of PRMO in different clinical stages ([Table 2](#t0010){ref-type="table"}) {#s0070}
------------------------------------------------------------------------------------------

PRMO was assessed in different clinical stages. The mean of PRMO was found to be 16% in clinical stage I, 35.60% in stage II, and 47.56% in stage III. The F value was 8.105 when analyzed with Fisher's exact test by ANOVA software showing very high significance with a *p* value of \<0.001.Table 2Assessment of PRMO in different clinical stages.Clinical stagingNMeanStandard deviationMinimumMaximumI216.001.4141517II3035.6014.675763III1847.569.7032973[^1]

3.3. Assessment of PRMO in different histopathological grading of OSF ([Table 3](#t0015){ref-type="table"}) {#s0075}
-----------------------------------------------------------------------------------------------------------

PRMO was assessed in different histopathological grades. The mean of PRMO was found to be 17% in grade I, 25.91% in grade II, 43.21% in grade III, and 45.6% in grade IV. The F value was 7.342 when analyzed with Fisher's exact test by ANOVA software with very high significance with a *p* value of \<0.001.Table 3Assessing PRMO in different histopathological grades.Histopathological gradesNMeanStandard deviationMinimumMaximumI117.00.1717II1125.9113.277748III3343.2112.4892073IV545.6012.6813063[^2]

3.4. Proposed staging system and its correlation to histopathological grading ([Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}) {#s0080}
--------------------------------------------------------------------------------------------------------------------------------------------------------

In the proposed three-stage staging system, the PRMO in stage I was \<30%, in stage II was 30--45%, and in stage III was \>45% ([Table 4](#t0020){ref-type="table"}). These values were then correlated with the histopathological grading by the chi-square test. The chi-square value of 11.585 obtained a *p* value of \<0.021, suggesting a good significance ([Table 5](#t0025){ref-type="table"}).Table 4Proposed staging.Proposed stagingPercentage of reduction in mouth openingFrequencyPercentI\<301530.0II30--451632.0III\>451938.0  Total50100.0Table 5Correlation of proposed staging to histopathological staging.PRMO in percentageTotal\<30%30--45%\>45%Histopathological gradingI & IICount83112%53.3%18.8%5.3%24.0%IIICount6121533%40.0%75.0%78.9%66.0%IVCount1135%6.7%6.3%15.8%10.0%  TotalCount15161950%100.0%100.0%100.0%100.0%[^3]

4. Discussion {#s0085}
=============

OSF is a chronic progressive disease of the oral cavity characterized by atrophic epithelium and fibrotic band formation leading to restricted mouth opening. The disease has remarkable morbidity caused by limitation of mouth opening and mortality because it can transform into squamous cell carcinoma. The severity of disease morbidity is assessed by evaluating the maximum mouth opening measurement of an individual. Various authors have proposed different staging patterns to assess OSF progression. These staging proposals were mostly based on distribution and location of fibrous bands in the oral cavity ([@b0040], [@b0025]). Another staging proposal was based on mouth opening measurements in OSF patients ([@b0040], [@b0025], [@b0085]), however many of the OSF staging systems do not consider the normal mouth opening limit of a person when assessing reduction in mouth opening. In this study we have considered the normal maximum mouth opening capacity of an individual in assessing the reduction in mouth opening.

The present study was performed on 50 subjects between the ages of 20 and 50 years old with the mean age of 28.94 years old. Of the subjects, 70% were in the 20- to 30-year-old age group. It is alarming to see that OSF is now being seen at such an early age. This observation has been documented in many studies done around the world ([@b0075], [@b0040]). This could be because of the easy accessibility of areca products in youngsters. Among the 50 subjects, 47 (94%) patients were males, which suggests that there is a strong male predilection for OSF in the present study group. This result is in accordance with the study conducted by [@b0110], [@b0035]. The reports of sex distribution in OSF are varied; [@b0095] showed equal sex distribution, whereas [@b0090] reported female predominance (F:M = 8:3). The incidence in gender ratio varies from study to study probably because of varying habits in various populations. Females in the villages consume local pan, and males mainly use processed betel nut with local pan. This may be the main reason for male predominance in OSF in the current research.

The various clinical and functional stagings were done earlier without considering the normal maximum mouth-opening limit of an individual ([@b0040], [@b0025], [@b0080], [@b0045], [@b0085]). The TFI is an established method to estimate a normal maximum mouth-opening limit in an individual and was used by different authors ([@b0030], [@b0115], [@b0010]). The study conducted in a south Indian population demonstrated that the subjects were able to vertically align their right and left three fingers between the upper and lower central incisors up to the first distal interphalangeal folds. It suggests that the width of three fingers can be used as a "tool" to distinguish *normal* from *restricted* mouth opening. Hence the TFI measurement is the normal range in our population when estimating reduction by [@b0010].

In our study we measured the maximum interincisal distance and the TFI by using a Vernier caliper. Later, the severity of disease was calculated by assessing PRMO. Alhough PRMO was assessed at different clinical stages as suggested by [@b0040], we obtained a range between 16% and 47%, and statistically the *p* value of \<0.001 was highly significant (see [Table 2](#t0010){ref-type="table"}). Similarly, a range between 17% and 45.6% was obtained when PRMO was assessed at different histopathological gradings as suggested by [@b0095]. Again, the statistical value was highly significant with a *p* value of \<0.001 (see [Table 3](#t0015){ref-type="table"}). In the proposed three-stage staging system in which PRMO in stage I was \<30%, in stage II was 30--45%, and in stage III was \>45%, the results are correlated with the histopathological grading by Pearson's chi-square test in which the chi-square value of 11.585 was obtained with a significant *p* value of \<0.021 (see [Table 5](#t0025){ref-type="table"}).

With the above findings we believe that the following clinical staging pattern can be adapted.Stage I \< 30%Stage II 30--45%Stage III \> 45%

Many authors ([@b0070], [@b0065], [@b0005], [@b0050]) have attempted to correlate clinicohistopathological features with the older staging system without considering the amount of normal mouth opening; none of those studies showed significant correlations. This strongly indicates the need of the proposed staging system to be implemented in staging OSF.

5. Conclusion {#s0090}
=============

With the data obtained from this study, the following clinical staging pattern can be adapted. Stage I of PRMO is \<30%, Stage II between 30--45%, and stage III is \>45%. Hence it may be appropriate to assess the disease severity and stage by assessing the degree of disability (i.e., mouth opening reduction considering the individual's normal mouth opening ability). The determination of PRMO may be a useful tool in this direction. Hence we encourage more studies on this topic with larger sample sizes in the future so that each clinical and histopathological stage is represented by adequate numbers.
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[^1]: *p* Value was significant at *p* \< 0.001.

[^2]: *p* Value was very highly significant at *p* \< 0.001.

[^3]: *p* Value was highly significant at *p* \< 0.021.
